What’s driving the wild swings in Telix shares?

Telix Pharmaceuticals Ltd (ASX: TLX) shares are all over the place. The ASX biotech stock is down 5% over the past five trading days, yet up 16% over the past month and 27% year to date.

Zoom out further and the picture flips again. Telix shares are still down 43% over the past 12 months, having fallen sharply from around $29.64 this time last year to as low as $8.26 in February. It’s trading at $14.32 per share at the time of writing.

So, what’s behind the volatility?

Multiple growth levers

Let’s start with the fundamentals. Telix operates in the fast-growing field of radiopharmaceuticals, developing imaging and therapeutic products for cancer care. Its lead product, Illuccix, is already generating revenue, particularly in the US market, and provides a strong commercial foundation.

That’s a key strength for Telix shares. Unlike many biotech companies, Telix is not purely speculative. It has an established product, growing sales, and a pipeline of additional candidates targeting areas such as kidney and brain cancer.

Recent updates have also been encouraging. The company continues to expand its commercial footprint while advancing its pipeline, giving investors multiple potential growth drivers over time.

Regulatory and valuation risks

But biotech rarely trades in a straight line. The flipside of that growth potential is risk. Earnings can be uneven, regulatory approvals are never guaranteed, and sentiment can shift quickly based on news flow. Clinical results, product launches, and even broader healthcare sector trends can all trigger sharp moves in the share price.

Valuation is another factor. After a strong run earlier in its lifecycle, Telix shares were priced for high expectations. When sentiment toward growth stocks weakened, the pullback was severe. Even now, the stock remains sensitive to any changes in outlook.

That helps explain the wide trading range over the past year. Short-term movements are often driven more by sentiment than fundamentals. Positive announcements can spark sharp rallies, while periods of limited news or broader market caution can lead to equally sharp pullbacks.

What next for Telix shares?

Despite the wild swings, analysts remain firmly in the bullish camp.

According to TradingView data, all 16 brokers covering Telix shares rate them as a buy or strong buy. The average price target sits at $24.44, implying around 71% upside from current levels.

Some are even more optimistic. The most bullish target stands at $31.01, suggesting potential upside of 116% if the company delivers on expectations.

So where does that leave investors?

Telix is a classic high-growth healthcare stock. It offers significant upside potential, backed by a commercial product and expanding pipeline, but it also comes with volatility.

The bottom line is simple. The swings in Telix shares reflect a mix of strong fundamentals, high expectations, and shifting market sentiment.

For investors, that means opportunity, but also a need for patience and a tolerance for bumps along the way.

The post What’s driving the wild swings in Telix shares? appeared first on The Motley Fool Australia.

More reading

• 3 exciting ASX shares you won’t want to miss out on
• Up 68% from a multi-year low. Are Telix shares a buy, sell or hold?
• 3 ASX 200 shares tipped to rise 20% or more
• These are the 10 most shorted ASX shares
• Is the Telix share price heading to $19? This broker thinks it is

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.